NDAORALFOR SUSPENSION, DELAYED RELEASE
Approved
May 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
PREVACID (lansoprazole) by Takeda is proton pump inhibitors [moa]. First approved in 2001.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PREVACID (lansoprazole) is an oral proton pump inhibitor that suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells. It is indicated for gastroesophageal reflux disease, erosive esophagitis, duodenal ulcer, gastric ulcer, and heartburn. The delayed-release oral suspension formulation enables targeted delivery to the small intestine for optimal acid suppression.
LOE Approaching
Declining
With $11M in spending and LOE approaching, PREVACID is in a managed decline phase; expect smaller commercial teams focused on retention and generics transition support.
Mechanism of Action
Proton Pump Inhibitors
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
Started Mar 2026
1,050 enrolled
GERD (Gastroesophageal Reflux Disease)
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
Started Sep 2025
500 enrolled
GERD (Gastroesophageal Reflux Disease)
Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 Months
Started Jun 2025
0Pediatric Gastroesophageal Reflux Disease
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
Started May 2023
24 enrolled
Erosive Esophagitis
The Efficacy and Safty of Proton Pump Inhibitor (Lansoprazole)
Started May 2023
300 enrolled
Coronary Artery Disease
Worked on PREVACID at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.